羟苯磺酸钙治疗糖尿病视网膜病变血浆ET-1和CGRP的变化研究

目的 观察羟苯磺酸钙治疗糖尿病视网膜病变(DR)患者血浆内皮素1(ET-1)、降钙素基因相关肽(CGRP)含量的动态变化.方法 自身前后对照方法.羟苯磺酸钙治疗100例DR患者,应用放射免疫分析(RIA)检测患者血浆ET-1、CGRP的浓度.观察时间分为服用药物前和服药后2周、1月、3月、半年共5个时间点.结果 DR患者服用药物前血浆ET-1、CGRP含量分别为(186.15±43.89)ng/L、(46.37±13.28)ng/L.服用药物治疗后不同时间(2周、1月、3月、6月)ET-1含量分别为(153.82±39.54)、(121.27±38.45)、(72.61±30.24)和(71.89±24.37)ng/L;CGRP含量分别为(43.42±12.78)、(59.65±15.72)、(68.87±25.36)和(67.91±24.75)ng/L.结果显示,羟苯磺酸钙治疗后,患者血浆ET-1、CGRP含量发生变化,ET-1降低,CGRP升高,ET-1/CGRP比值降低接近正常水平.结论 提示血浆ET-1、CGRP在羟苯磺酸钙治疗DR可能起着重要的病理作用,其对DR诊治疗效的随访判定有一定的应用参考价值.

Changes of plasma endothelin-1 (ET-1) and calcitonin gene related peptide (CGRP) of calcium dobesilate in treatment of diabetic retinopathy

Objective To observe the changes of plasma endothelin-1 (ET-1) and calcitonin gene related peptide (CGRP) of calciurn dobesilate in treatment of diabetic retinopathy (DR). Methods This is a self-control trial. Plasma ET-1 and CGRP concentrations were measured with RIA in 100 patients with DR received calcium dobesilate (pretherapy, post-treatment: 2w, 1m, 3m and 6m). Results The content of plasma ET-1 were 186.15±43.89, 153.82±39.54, 121.27±38.45, 72.61±30.24 and 71.89±24.37ng/L at pretherapy and post-treatment (2w, 1m, 3m, 6m), respectively; that of plasma CGRP were 46.37±13.28, 43.42±12.78, 59.65±15.72, 68.87±25.36 and 67.91±24.75ng/L. After receiving the treatment with calcium dobesilate, the content of plasma ET-1 decreased and CGRP increased gradually. Conclusions Plasma ET-1 and CGRP play an important role in the whole patho-physiologic process in the DR treatment with calcium dobesilate, and measurement of their plasma concentrations may predict the curative effect on the DR follow-up.